Lv1
15 积分 2022-01-12 加入
The Proposed 9th Edition TNM Classification of Lung Cancer
2天前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
25天前
已完结
Claudin18.2 expression and its clinicopathological feature in adenocarcinoma from various parts
7个月前
已完结
[China guidelines on prevention and treatment of nausea and vomiting caused by antitumor therapies (2023 edition)]
9个月前
已完结
Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms
1年前
已完结
Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter study
1年前
已完结
A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer
1年前
已完结
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma
1年前
已完结
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
1年前
已完结
免疫检查点抑制剂引起的内分泌系统免疫相关不良反应专家共识(2020)
1年前
已完结
皖公网安备34019202002308
